Tag: lanreotide

edda gomez panzani md

In Memoriam: Edda Gomez-Panzani, MD

July 9, 2015

It is with deep sorrow that we learned of the passing of Edda Gomez-Panzani, MD on June 30, 2015. The NorCal CarciNET Community shared a tribute to Edda who “was instrumental in gaining FDA approval for Somatuline (lanreotide) for NETs patients …

READ MORE
immunotherapy researchers june hu kunz

10 Highlights of the Year 2014 for the Carcinoid and Neuroendocrine Tumor Community

December 18, 2014

As the Carcinoid Cancer Foundation looks back on the year 2014, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

READ MORE
fda logo

Breaking News: US FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors

December 16, 2014

December 16, 2014: The US Food and Drug Administration (FDA) today approved “lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic

READ MORE
jim weiveris

10 Highlights of the Year 2013 for the Carcinoid and Neuroendocrine Tumor Community

December 18, 2013

As the Carcinoid Cancer Foundation looks back on the year 2013, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

READ MORE
Zebra

Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial

June 17, 2011

Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel),  a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …

READ MORE